Grifols, S.A. (FRA:G0FB)

Germany flag Germany · Delayed Price · Currency is EUR
7.50
+0.10 (1.35%)
At close: Dec 5, 2025
17.19%
Market Cap 6.53B
Revenue (ttm) 7.52B
Net Income (ttm) 372.72M
Shares Out n/a
EPS (ttm) 0.55
PE Ratio 17.51
Forward PE 10.30
Dividend 0.12 (1.64%)
Ex-Dividend Date Aug 12, 2025
Volume n/a
Average Volume 58
Open 7.50
Previous Close 7.40
Day's Range 7.50 - 7.50
52-Week Range 5.75 - 9.55
Beta n/a
RSI 51.42
Earnings Date Feb 25, 2026

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1909
Employees 23,833
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol G0FB
Full Company Profile

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.

Financial Statements

News

There is no news available yet.